Sun-Young Jung1, Eun Jin Jang2, Seoung Wan Nam3, Hyuk Hee Kwon3, Seul Gi Im4, Dam Kim3, Soo-Kyung Cho3, Dalho Kim4, Yoon-Kyoung Sung3. 1. a College of Pharmacy , Chung-Ang University , Seoul , South Korea. 2. b Department of Information Statistics , Andong National University , Andong-si , South Korea. 3. c Department of Rheumatology , Hanyang University Hospital for Rheumatic Diseases , Seoul , South Korea. 4. d Department of Statistics , Kyungpook National University , Daegu , South Korea.
Abstract
OBJECTIVES: To explore the relative efficacy of oral pharmacologic interventions in the treatment of knee OA. METHODS: A systematic literature review was conducted using the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases to identify trials conducted in patients with knee OA with a minimum 6 weeks of follow-up. The standardized mean differences of the change from baseline to week 6 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain between the treatment groups were estimated using Bayesian random-effects network meta-analyses. Subgroup analyses of baseline pain status (high, pain score ≥60 mm; low, pain score <60 mm) were performed. RESULTS: Of 4067 manuscripts, 44 were included in the evidence synthesis. Etoricoxib had the highest ranking for improving WOMAC pain (probability of being top ranked, p (best) = .43) followed by naproxen (p (best) = .12), acetaminophen (AAP) (p (best) = .04), and celecoxib (p (best) = .02). The top three ranked interventions were etoricoxib, celecoxib and aceclofenac in the higher pain group, and tramadol, celecoxib, and diclofenac in the lower pain group. CONCLUSION: In the overall analysis, etoricoxib, celecoxib, and aceclofenac had the highest rankings for improving WOMAC pain. The ability to improve knee OA symptoms may differ depending on baseline pain and radiologic features.
OBJECTIVES: To explore the relative efficacy of oral pharmacologic interventions in the treatment of knee OA. METHODS: A systematic literature review was conducted using the MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases to identify trials conducted in patients with knee OA with a minimum 6 weeks of follow-up. The standardized mean differences of the change from baseline to week 6 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain between the treatment groups were estimated using Bayesian random-effects network meta-analyses. Subgroup analyses of baseline pain status (high, pain score ≥60 mm; low, pain score <60 mm) were performed. RESULTS: Of 4067 manuscripts, 44 were included in the evidence synthesis. Etoricoxib had the highest ranking for improving WOMAC pain (probability of being top ranked, p (best) = .43) followed by naproxen (p (best) = .12), acetaminophen (AAP) (p (best) = .04), and celecoxib (p (best) = .02). The top three ranked interventions were etoricoxib, celecoxib and aceclofenac in the higher pain group, and tramadol, celecoxib, and diclofenac in the lower pain group. CONCLUSION: In the overall analysis, etoricoxib, celecoxib, and aceclofenac had the highest rankings for improving WOMAC pain. The ability to improve knee OA symptoms may differ depending on baseline pain and radiologic features.
Authors: Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang Journal: Blood Adv Date: 2020-06-23
Authors: Alberto Magni; Piergiuseppe Agostoni; Cesare Bonezzi; Giuseppe Massazza; Paolo Menè; Vincenzo Savarino; Diego Fornasari Journal: Pain Ther Date: 2021-04-19
Authors: Ruojin Li; Hongwei Chen; Jiahao Feng; Ying Xiao; Haoyang Zhang; Christopher Wai-Kei Lam; Hong Xiao Journal: Int J Environ Res Public Health Date: 2020-10-27 Impact factor: 3.390